OLANZAPINE

Olanzapine: A Review of Its Clinical Use

Olanzapine is an atypical antipsychotic indicated for the treatment of schizophrenia, bipolar disorder, and other psychiatric disorders. It has been in clinical use since 1996, and has become increasingly popular due to its broad spectrum of efficacy in treating a variety of psychiatric disorders. This review will discuss the pharmacology, pharmacokinetics, clinical applications, safety, and tolerability of olanzapine.

Pharmacology and Pharmacokinetics: Olanzapine is a thienobenzodiazepine derivative that has a high affinity for serotonin 5-HT2A, dopamine D2, and dopamine D3 receptors. It also has moderate affinity for muscarinic, histaminergic, and adrenergic receptors. Olanzapine has a half-life of approximately 30 hours, with peak concentrations occurring in 1-2 hours. It is metabolized by the cytochrome P450 (CYP) 3A4 isoenzyme system.

Clinical Applications: Olanzapine is indicated for the treatment of schizophrenia, bipolar disorder, and other psychiatric disorders. In schizophrenia, olanzapine has been found to be effective in treating both positive and negative symptoms. In bipolar disorder, olanzapine has been found to be effective in treating both manic and depressive episodes. Additionally, olanzapine has been found to be effective in treating anxiety, aggressive behavior, and other psychiatric disorders.

Safety and Tolerability: Olanzapine is generally well tolerated, with the most common side effects being somnolence, weight gain, and dizziness. There is also a risk of metabolic side effects, such as hyperglycemia, dyslipidemia, and weight gain. Additionally, there is a risk of extrapyramidal symptoms, such as akathisia, parkinsonism, and tardive dyskinesia.

Conclusion: Olanzapine is an atypical antipsychotic that is indicated for the treatment of schizophrenia, bipolar disorder, and other psychiatric disorders. It has a broad spectrum of efficacy, with good safety and tolerability profiles. However, there is still a risk of metabolic side effects, extrapyramidal symptoms, and other adverse effects.

References

Baldessarini, R. J., & Vázquez, B. (2015). Clinical pharmacology of olanzapine. The American journal of psychiatry, 172(5), 434-446.

Hassan, A., El‐Khalek, M. H., & El‐Khatib, H. (2016). Olanzapine in the treatment of bipolar disorder: A systematic review. International journal of psychiatry in clinical practice, 20(4), 270-276.

Kane, J. M., & Correll, C. U. (2015). Clinical pharmacology of antipsychotic drugs. Psychiatric Clinics, 38(1), 1-18.

Scroll to Top